LRRK2 (PARK8) Mutant I2020T Antibody Blocking peptide
LRRK2 (PARK8) Mutant I2020T Antibody Blocking peptide
Product Specifications
Product Name Alternative
Leucine-rich repeat serine/threonine-protein kinase 2, Dardarin, LRRK2, PARK8
UniProt
Q5S007
Field of Research
Cell Biology
Form
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Notes
For research use only.
Applications Notes
Synthetic peptide
AA Sequence
The synthetic peptide sequence was selected from the I2020 region of human LRRK2 (PARK8) Mutant I2020T. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040276-100 1x 100 µL
TAG-72 / CA72.4 (B72.3), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880009-500 1x 500 µL
MART-1 / Melan-A (M2-7C10), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740977-500 1x 500 µL
TGF-beta (1D11.16.8), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC472302-500 1x 500 µL
MUC18 / CD146 / MCAM (Melanoma Cell Adhesion Molecule) (rMUC18/1130), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940012-500 1x 500 µL
Tyrosinase (T311), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC882750-100 1x 100 µL
S100A4 (Marker of Tumor Metastasis) (S100A4/2750R), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details